JP2005519985A5 - - Google Patents

Download PDF

Info

Publication number
JP2005519985A5
JP2005519985A5 JP2003585726A JP2003585726A JP2005519985A5 JP 2005519985 A5 JP2005519985 A5 JP 2005519985A5 JP 2003585726 A JP2003585726 A JP 2003585726A JP 2003585726 A JP2003585726 A JP 2003585726A JP 2005519985 A5 JP2005519985 A5 JP 2005519985A5
Authority
JP
Japan
Prior art keywords
weight
patient
activator
composition
unit dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003585726A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005519985A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2003/012235 external-priority patent/WO2003088974A1/en
Publication of JP2005519985A publication Critical patent/JP2005519985A/ja
Publication of JP2005519985A5 publication Critical patent/JP2005519985A5/ja
Pending legal-status Critical Current

Links

JP2003585726A 2002-04-19 2003-04-21 医薬組成物 Pending JP2005519985A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37410302P 2002-04-19 2002-04-19
US60/374,103 2002-04-19
PCT/US2003/012235 WO2003088974A1 (en) 2002-04-19 2003-04-21 Pharmaceutical composition

Publications (2)

Publication Number Publication Date
JP2005519985A JP2005519985A (ja) 2005-07-07
JP2005519985A5 true JP2005519985A5 (enExample) 2005-09-29

Family

ID=29251138

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003585726A Pending JP2005519985A (ja) 2002-04-19 2003-04-21 医薬組成物

Country Status (29)

Country Link
US (21) US7320968B2 (enExample)
EP (2) EP1741433B1 (enExample)
JP (1) JP2005519985A (enExample)
KR (2) KR100952786B1 (enExample)
CN (2) CN102357098B (enExample)
AR (2) AR039644A1 (enExample)
AT (1) ATE371456T1 (enExample)
AU (1) AU2003228612B2 (enExample)
BR (1) BR0309390A (enExample)
CA (1) CA2470200C (enExample)
CY (1) CY1109005T1 (enExample)
DE (1) DE60315939T2 (enExample)
DK (1) DK1425019T3 (enExample)
EA (1) EA009839B1 (enExample)
EG (1) EG24882A (enExample)
ES (2) ES2292964T3 (enExample)
IL (1) IL164547A (enExample)
IS (2) IS2667B (enExample)
LT (1) LT5235B (enExample)
LV (1) LV13303B (enExample)
MX (1) MXPA04010311A (enExample)
MY (1) MY139721A (enExample)
NO (1) NO335864B1 (enExample)
NZ (1) NZ535970A (enExample)
PL (1) PL213976B1 (enExample)
SA (1) SA03240158B1 (enExample)
TW (1) TWI362932B (enExample)
WO (1) WO2003088974A1 (enExample)
ZA (1) ZA200408422B (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040092494A9 (en) * 2000-08-30 2004-05-13 Dudley Robert E. Method of increasing testosterone and related steroid concentrations in women
US20030139384A1 (en) * 2000-08-30 2003-07-24 Dudley Robert E. Method for treating erectile dysfunction and increasing libido in men
US20040002482A1 (en) * 2000-08-30 2004-01-01 Dudley Robert E. Androgen pharmaceutical composition and method for treating depression
US6503894B1 (en) 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
US7244703B2 (en) 2001-06-22 2007-07-17 Bentley Pharmaceuticals, Inc. Pharmaceutical compositions and methods for peptide treatment
US20040072810A1 (en) * 2001-11-07 2004-04-15 Besins International Belgique Pharmaceutical composition in the form of a gel or a solution based on dihydrotestosterone, process for preparing it and uses thereof
MY139721A (en) 2002-04-19 2009-10-30 Cpex Pharmaceuticals Inc Pharmaceutical composition
US20040259852A1 (en) * 2003-06-18 2004-12-23 White Hillary D. Trandsdermal compositions and methods for treatment of fibromyalgia and chronic fatigue syndrome
US8883769B2 (en) * 2003-06-18 2014-11-11 White Mountain Pharma, Inc. Methods for the treatment of fibromyalgia and chronic fatigue syndrome
ES2348303T3 (es) 2003-12-08 2010-12-02 Cpex Pharmaceuticals, Inc. Composiciones farmacauticas y procedimientos de tratamiento con insulina.
NZ553446A (en) * 2004-09-09 2010-05-28 Besins Int Lab Testosterone gels comprising propylene glycol as penetration enhancer
EP1634583A1 (en) * 2004-09-09 2006-03-15 Laboratoires Besins International Testosterone gels comprising propylene glycol as penetration enhancer
US20070088012A1 (en) * 2005-04-08 2007-04-19 Woun Seo Method of treating or preventing type-2 diabetes
CA2624788C (en) 2005-10-12 2011-04-19 Unimed Pharmaceuticals, Llc Improved testosterone gel and method of use
KR20110010763A (ko) * 2008-05-09 2011-02-07 톨마 인코포레이티드 피부/점막 질환을 치료하기 위한 프로구아닐
CN102056593A (zh) * 2008-06-05 2011-05-11 Cpex药品公司 胰岛素鼻用制剂
US20110097363A1 (en) * 2009-10-22 2011-04-28 Cpex Pharmaceuticals, Inc. Therapeutically Effective Preparations of Insulin
US9642863B2 (en) 2010-11-18 2017-05-09 White Mountain Pharma, Inc. Methods for treating chronic or unresolvable pain and/or increasing the pain threshold in a subject and pharmaceutical compositions for use therein
US20130045958A1 (en) 2011-05-13 2013-02-21 Trimel Pharmaceuticals Corporation Intranasal 0.15% and 0.24% testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder
US9757388B2 (en) 2011-05-13 2017-09-12 Acerus Pharmaceuticals Srl Intranasal methods of treating women for anorgasmia with 0.6% and 0.72% testosterone gels
AR086400A1 (es) 2011-05-13 2013-12-11 Trimel Pharmaceuticals Corp Formulaciones en gel intranasal de testosterona en dosis de menor potencia y uso de las mismas para el tratamiento de la anorgasmia o el trastorno de deseo sexual hipoactivo
JP6152092B2 (ja) * 2011-05-15 2017-06-28 エーセラス ファーマシューティカルズ コーポレーション 経鼻投与のための徐放テストステロン鼻腔内ゲル、方法および複数回用量プレフィルアプリケーターシステム
US10568905B2 (en) * 2012-02-14 2020-02-25 Metabolic Therapy Inc. Pharmaceutical composition and method for treating retinal neurodegeneration
US9950125B2 (en) 2012-04-06 2018-04-24 Antares Pharma, Inc. Needle assisted jet injection administration of testosterone compositions
EP2897768B1 (en) 2012-09-20 2020-07-22 GKN Armstrong Wheels, Inc. Lock ring spreader
US11744838B2 (en) 2013-03-15 2023-09-05 Acerus Biopharma Inc. Methods of treating hypogonadism with transnasal testosterone bio-adhesive gel formulations in male with allergic rhinitis, and methods for preventing an allergic rhinitis event
US8785426B1 (en) 2013-12-13 2014-07-22 Upsher-Smith Laboratories, Inc. Testosterone gel compositions and related methods
US20170014417A1 (en) 2015-07-14 2017-01-19 Lipp Life Sciences Llc Pharmaceutical administration system for the transdermal application of vardenafil
WO2019089942A1 (en) * 2017-11-02 2019-05-09 Rick Coulon Formulations for use in the transdermal delivery of proteasome inhibitors
CN112666197B (zh) * 2020-11-29 2022-11-04 山东大学 一种用于tbm的岩渣石英含量测试系统及方法

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3991203A (en) 1975-06-19 1976-11-09 Nelson Research & Development Company Vehicle composition containing 1-substituted azacyclopentan-2-ones
US3989815A (en) 1975-06-19 1976-11-02 Nelson Research & Development Company Novel N-bis-azacyclopentan-2-onyl alkanes
US3989816A (en) 1975-06-19 1976-11-02 Nelson Research & Development Company Vehicle composition containing 1-substituted azacycloheptan-2-ones
US4316893A (en) 1975-06-19 1982-02-23 Nelson Research & Development Co. Vehicle composition containing 1-substituted azacycloalkan-2-ones
US4405616A (en) 1975-06-19 1983-09-20 Nelson Research & Development Company Penetration enhancers for transdermal drug delivery of systemic agents
BE843140A (fr) 1975-06-19 1976-10-18 Aazacycloalcan-2-ones 1-substituees et compositions pharmaceutiques contenant ces composes a titre d'excipients
US4423040A (en) 1980-04-04 1983-12-27 Nelson Research & Development Company Vehicle composition containing 1-substituted azacyclohexan-2-ones
US4424210A (en) 1980-04-04 1984-01-03 Nelson Research & Development Company Vehicle composition containing 1-substituted azacycloalkan-2-ones
US4415563A (en) 1980-04-04 1983-11-15 Nelson Research & Development Company Vehicle composition containing 1-substituted azacyclononan-2-ones
US4444762A (en) 1980-04-04 1984-04-24 Nelson Research & Development Company Vehicle composition containing 1-substituted azacyclopentan-2-ones
US5731303A (en) 1985-12-04 1998-03-24 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery compositions
US5023252A (en) * 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5270346A (en) 1986-01-31 1993-12-14 Whitby Research, Inc. Penetration enhancers for transdermal delivery of systemic agents
US4992422A (en) 1986-01-31 1991-02-12 Whitby Research, Inc. Compositions comprising 1-substituted azacycloalkanes
US4801586A (en) 1986-04-23 1989-01-31 Nelson Research & Development Co. Penetration enhancers for transdermal delivery of systemic agents
US4879275A (en) 1987-09-30 1989-11-07 Nelson Research & Development Co. Penetration enhancers for transdermal delivery of systemic agent
US5019395A (en) 1988-03-08 1991-05-28 Warner-Lambert Company Compositions with enhanced penetration
US5676968A (en) * 1991-10-31 1997-10-14 Schering Aktiengesellschaft Transdermal therapeutic systems with crystallization inhibitors
US6190691B1 (en) 1994-04-12 2001-02-20 Adolor Corporation Methods for treating inflammatory conditions
GB9516268D0 (en) 1995-08-08 1995-10-11 Danbiosyst Uk Compositiion for enhanced uptake of polar drugs from the colon
DE19619045C1 (de) 1996-05-02 1997-11-13 Jenapharm Gmbh Verwendung von Kombinationspräparaten zur Behandlung hypogonadaler Männer sowie Männern mit Hypophysenerkrankungen
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
US6019997A (en) * 1997-01-09 2000-02-01 Minnesota Mining And Manufacturing Hydroalcoholic compositions for transdermal penetration of pharmaceutical agents
DE19701949A1 (de) 1997-01-13 1998-07-16 Jenapharm Gmbh Transdermales therapeutisches System
ATE275963T1 (de) 1997-01-30 2004-10-15 Novartis Pharma Gmbh Ölfreie pharmazeutische zusammensetzung welche cyclosporin enthält
DE29704393U1 (de) 1997-03-11 1997-07-17 Aesculap Ag, 78532 Tuttlingen Vorrichtung zur präoperativen Bestimmung der Positionsdaten von Endoprothesenteilen
US5968919A (en) * 1997-10-16 1999-10-19 Macrochem Corporation Hormone replacement therapy drug formulations for topical application to the skin
KR100648536B1 (ko) 1997-11-10 2006-11-24 셀러지 파마세우티칼스, 인크 침투 보강 및 자극 감소를 위한 계
US6980952B1 (en) * 1998-08-15 2005-12-27 Texas Instruments Incorporated Source normalization training for HMM modeling of speech
EP1031564A1 (en) 1999-02-26 2000-08-30 Klinge Pharma GmbH Inhibitors of cellular nicotinamide mononucleotide formation and their use in cancer therapy
FR2801507B1 (fr) 1999-11-30 2003-06-27 Pf Medicament Dispositif transdermique auto-adhesif comprenant un reservoir et une matrice contenant le meme principe actif, son procede de preparation et ses utilisations
NZ513964A (en) * 1999-12-08 2004-01-30 Pharmacia Corp Solid-state form of celecoxib having enhanced bioavailability
US6495124B1 (en) 2000-02-14 2002-12-17 Macrochem Corporation Antifungal nail lacquer and method using same
ATE485837T1 (de) * 2000-08-03 2010-11-15 Antares Pharma Ipl Ag Zusammensetzung zur transdermalen und/oder transmukosalen verabreichung von wirkstoffen, die ausreichende therapeutische spiegel garantiert
US7198801B2 (en) * 2000-08-03 2007-04-03 Antares Pharma Ipl Ag Formulations for transdermal or transmucosal application
US20040198706A1 (en) 2003-03-11 2004-10-07 Carrara Dario Norberto R. Methods and formulations for transdermal or transmucosal application of active agents
US20030139384A1 (en) 2000-08-30 2003-07-24 Dudley Robert E. Method for treating erectile dysfunction and increasing libido in men
JP2004524267A (ja) 2000-08-30 2004-08-12 ユニメッド・ファーマシューティカルズ・インコーポレーテッド 男性の勃起障害の治療方法、及び性衝動の増強方法
US6503894B1 (en) * 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
JP2004507511A (ja) * 2000-08-30 2004-03-11 ユニメッド・ファーマシューティカルズ・インコーポレーテッド 女性におけるテストステロンおよび近縁ステロイド濃度を増大させる方法
US20040002482A1 (en) 2000-08-30 2004-01-01 Dudley Robert E. Androgen pharmaceutical composition and method for treating depression
US20040092494A9 (en) 2000-08-30 2004-05-13 Dudley Robert E. Method of increasing testosterone and related steroid concentrations in women
US6743448B2 (en) 2000-12-11 2004-06-01 Abraham H. Kryger Topical testosterone formulations and associated methods
DK1347764T3 (da) 2000-12-22 2007-07-23 August Wolff Gmbh & Co Kg Arzn Gelpræparat på alkoholisk basis til behandling af hypogonadisme ved transskrotal applikation
US20030027833A1 (en) * 2001-05-07 2003-02-06 Cleary Gary W. Compositions and delivery systems for administration of a local anesthetic agent
US20030027804A1 (en) 2001-06-27 2003-02-06 Van Der Hoop Roland Gerritsen Therapeutic combinations for the treatment of hormone deficiencies
US7169107B2 (en) 2002-01-25 2007-01-30 Karen Jersey-Willuhn Conductivity reconstruction based on inverse finite element measurements in a tissue monitoring system
PL373593A1 (en) 2002-03-15 2005-09-05 Unimed Pharmaceuticals, Inc. Androgen pharmaceutical composition and method for treating depression
MY139721A (en) * 2002-04-19 2009-10-30 Cpex Pharmaceuticals Inc Pharmaceutical composition
US20040259784A1 (en) 2003-06-18 2004-12-23 White Hillary D. Compositions and methods for treatment of muscle pain and muscle wasting

Similar Documents

Publication Publication Date Title
JP2005519985A5 (enExample)
CA2309688C (en) Penetration enhancing and irritation reducing systems
EP2062575B1 (en) Adhesive preparation comprising desglymidodrine
JPS61502760A (ja) 粘着性経皮投与層
JP2005519985A (ja) 医薬組成物
HU228863B1 (en) Topical hormonal composition containing synthetic progestogen with systemic effect
WO1988001170A1 (fr) Preparation pour l'utilisation externe contenant des medicaments steroides
CN104039305B (zh) 含有二氧化碳的组合物的制备用试剂盒
CN100341577C (zh) 经皮吸收制剂
US6685959B1 (en) Pharmaceutical compositions comprising 2-isoxazoles-8-aminotetralin derivatives
JP2006514665A (ja) 慢性心不全および／または上昇したコレステロールレベルを処置するための方法
TWI343259B (en) Pharmaceutical composition in the form of a hydrogel for transdermal administration of active ingredients
JP4705343B2 (ja) 経皮吸収製剤用基剤およびこれを用いた皮膚貼付製剤
EP2062576B1 (en) Adhesive preparation comprising desglymidodrine
WO2003013548A1 (en) Medical composition for external use for dermatosis
CN116602942A (zh) 一种氟比洛芬凝胶贴膏及其制备方法
JP2003246737A (ja) 皮膚外用組成物
CN110115710B (zh) 一种用于治疗哮喘的透皮吸收制剂
CN120114421B (zh) 褪黑素透皮贴剂及其制备方法
JP2001187739A (ja) アレルギー性皮膚疾患治療用外用剤
CN111803469B (zh) 一种含雌二醇透皮吸收缓释贴片及其制备方法
JPH06336434A (ja) 骨格筋弛緩経皮吸収剤
JPH0710755A (ja) ブチロフェノン系経皮吸収剤組成物
JPH0193542A (ja) 医薬外用製剤
JPH06247846A (ja) 塩酸リトドリンの経皮吸収製剤用組成物